Aclaris Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
64
- Stock Symbol
-
ACRS
- Investments
-
3
- Share Price
-
$1.60
- (As of Friday Closing)
Aclaris Therapeutics General Information
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Contact Information
Website
www.aclaristx.comCorporate Office
- 701 Lee Road
- Suite 103
- Wayne, PA 19087
- United States
Corporate Office
- 701 Lee Road
- Suite 103
- Wayne, PA 19087
- United States
Aclaris Therapeutics Stock Performance
As of 21-Mar-2025, Aclaris Therapeutics’s stock price is $1.60. Its current market cap is $173M with 108M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.60 | $1.57 | $0.95 - $5.17 | $173M | 108M | 920K | -$1.71 |
Aclaris Therapeutics Financials Summary
As of 31-Dec-2024, Aclaris Therapeutics has a trailing 12-month revenue of $18.7M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 137,684 | 137,684 | (28,364) | 802,964 |
| Revenue | 18,720 | 18,720 | 31,249 | 29,752 |
| EBITDA | (130,865) | (130,865) | (87,248) | (86,111) |
| Net Income | (132,065) | (132,065) | (88,481) | (86,908) |
| Total Assets | 220,327 | 220,327 | 197,405 | 254,596 |
| Total Debt | 684 |
Aclaris Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aclaris Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aclaris Therapeutics Comparisons
Industry
Financing
Details
Aclaris Therapeutics Competitors (22)
One of Aclaris Therapeutics’s 22 competitors is Aquapharm (Scotland ), a Formerly VC-backed company based in Oban, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aquapharm (Scotland ) | Formerly VC-backed | Oban, United Kingdom | ||||
| Ipsen (Pharmaceuticals) | Formerly PE-Backed | Boulogne Billancourt, France | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Dermata | Formerly VC-backed | San Diego, CA |
Aclaris Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aclaris Therapeutics Patents
Aclaris Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230286950-A1 | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds | Inactive | 04-Feb-2022 | ||
| CA-3208215-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | ||
| AU-2022224689-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | ||
| EP-4294809-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | ||
| US-20240139170-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | A61K31/4545 |
Aclaris Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aclaris Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aclaris Therapeutics Investments & Acquisitions (3)
Aclaris Therapeutics’s most recent deal was a Corporate Asset Purchase with Allergan (Worldwide Rights to RHOFADE) for . The deal was made on 15-Oct-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allergan (Worldwide Rights to RHOFADE) | 15-Oct-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Confluence Discovery Technologies | 03-Aug-2017 | Merger/Acquisition | Drug Discovery | ||
| Vixen Pharmaceuticals | 24-Mar-2016 | Merger/Acquisition | Drug Discovery |
Aclaris Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 15, 2023
32.74 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 421
Rank
Percentile
Aclaris Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Confluence Discovery Technologies | Saint Louis, MO | 2010 |
Aclaris Therapeutics FAQs
-
When was Aclaris Therapeutics founded?
Aclaris Therapeutics was founded in 2012.
-
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics is headquartered in Wayne, PA.
-
What is the size of Aclaris Therapeutics?
Aclaris Therapeutics has 64 total employees.
-
What industry is Aclaris Therapeutics in?
Aclaris Therapeutics’s primary industry is Drug Discovery.
-
Is Aclaris Therapeutics a private or public company?
Aclaris Therapeutics is a Public company.
-
What is Aclaris Therapeutics’s stock symbol?
The ticker symbol for Aclaris Therapeutics is ACRS.
-
What is the current stock price of Aclaris Therapeutics?
As of 21-Mar-2025 the stock price of Aclaris Therapeutics is $1.60.
-
What is the current market cap of Aclaris Therapeutics?
The current market capitalization of Aclaris Therapeutics is $173M.
-
What is Aclaris Therapeutics’s current revenue?
The trailing twelve month revenue for Aclaris Therapeutics is $18.7M.
-
Who are Aclaris Therapeutics’s competitors?
Aquapharm (Scotland ), Ipsen (Pharmaceuticals), Novartis, Biogen, and Dermata are some of the 22 competitors of Aclaris Therapeutics.
-
What is Aclaris Therapeutics’s annual earnings per share (EPS)?
Aclaris Therapeutics’s EPS for 12 months was -$1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
